Who Paid My Doc
Ryan Westergaard
Infectious Disease Madison, WI Medical Doctor
NPI 1255423737 CMS profile 911164
600 Highland Ave, Madison, WI 53792
General payments
$75
Research payments
$0
Ownership & investment interest
$0
Through program year 2019, Ryan Westergaard of Madison, WI is reported in the CMS Open Payments database as having received $75 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 20th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $75 | 1 |
Beside peers
- Ryan Westergaard
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Ryan Westergaard were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Ryan Westergaard | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $75 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $0 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $0 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
183
Drug cost
$248,466
Branded share of claims
79.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 15 | $59,266 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 17 | $58,172 | |
| Prezcobix Darunavir/Cobicistat | Brand | 19 | $45,909 | |
| Isentress Raltegravir Potassium | Brand | 21 | $39,562 | |
| Maraviroc | Generic | 14 | $24,350 | |
| Abacavir-Lamivudine Abacavir Sulfate/Lamivudine | Brand | 11 | $11,506 | |
| Shingrix Varicella-Zoster Ge/As01b/Pf | Brand | 36 | $6,542 | |
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | Brand | 11 | $3,045 | |
| Bupropion Hcl Sr Bupropion Hcl | Brand | 15 | $83 | |
| Sertraline Hcl | Generic | 12 | $30 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Infectious Disease in Wisconsin
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Wisconsin
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.